Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CBIO NASDAQ:CDXS NASDAQ:DOMH NASDAQ:VNDA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCBIOCrescent Biopharma$12.85+16.8%$0.00$10.83▼$63.00$251.22M1.51123,551 shs44,494 shsCDXSCodexis$2.77-0.4%$2.65$1.90▼$6.08$229.48M2.54780,368 shs860,695 shsDOMHDominari$5.73-0.2%$5.23$0.83▼$13.58$83.91M0.5274,855 shs343,933 shsVNDAVanda Pharmaceuticals$4.20$4.62$3.81▼$5.55$248.17M0.72549,772 shs304,475 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCBIOCrescent Biopharma0.00%+7.08%-4.81%-98.32%-98.32%CDXSCodexis0.00%+2.97%-10.93%+12.60%-8.28%DOMHDominari0.00%+27.33%+19.87%-4.34%+267.31%VNDAVanda Pharmaceuticals0.00%+0.24%-15.83%+6.06%-19.23%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCBIOCrescent Biopharma3.0336 of 5 stars3.80.00.03.72.21.70.6CDXSCodexis3.8899 of 5 stars3.33.00.02.53.31.70.6DOMHDominari0.8635 of 5 stars0.03.00.00.02.42.50.0VNDAVanda Pharmaceuticals4.4071 of 5 stars3.81.00.04.22.73.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCBIOCrescent Biopharma 3.50Strong Buy$25.6799.74% UpsideCDXSCodexis 2.50Moderate Buy$11.00297.11% UpsideDOMHDominari 0.00N/AN/AN/AVNDAVanda Pharmaceuticals 3.50Strong Buy$16.50292.86% UpsideCurrent Analyst Ratings BreakdownLatest DOMH, VNDA, CBIO, and CDXS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/14/2025CBIOCrescent BiopharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$27.006/25/2025CBIOCrescent BiopharmaStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$28.006/20/2025CBIOCrescent BiopharmaTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/18/2025CBIOCrescent BiopharmaLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$22.005/14/2025VNDAVanda PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$13.005/13/2025VNDAVanda PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 8/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCBIOCrescent Biopharma$10K25,121.75N/AN/A$6.92 per share1.86CDXSCodexis$59.35M3.87N/AN/A$0.82 per share3.38DOMHDominari$18.15M4.62N/AN/A$5.71 per share1.00VNDAVanda Pharmaceuticals$198.77M1.25N/AN/A$8.23 per share0.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCBIOCrescent Biopharma-$37.88M-$34.93N/AN/AN/AN/A-106.06%-86.60%N/ACDXSCodexis-$65.28M-$0.99N/AN/AN/A-149.47%-118.47%-53.37%8/13/2025 (Estimated)DOMHDominari-$14.70M-$4.50N/A∞N/A-167.73%-91.67%-77.80%8/14/2025 (Estimated)VNDAVanda Pharmaceuticals-$18.90M-$1.13N/AN/AN/A-32.90%-12.89%-10.47%N/ALatest DOMH, VNDA, CBIO, and CDXS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025CDXSCodexis-$0.17N/AN/AN/A$14.18 millionN/A7/31/2025Q2 2025CBIOCrescent Biopharma-$2.69-$4.93-$2.24-$4.93N/AN/A7/31/2025Q2 2025VNDAVanda Pharmaceuticals-$0.34-$0.46-$0.12-$0.46$54.77 million$52.59 million5/14/2025Q1 2025CDXSCodexis-$0.20-$0.25-$0.05-$0.25$10.38 million$7.54 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCBIOCrescent BiopharmaN/AN/AN/AN/AN/ACDXSCodexisN/AN/AN/AN/AN/ADOMHDominariN/AN/AN/AN/AN/AVNDAVanda PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCBIOCrescent BiopharmaN/A9.219.21CDXSCodexis0.593.723.64DOMHDominariN/A5.745.74VNDAVanda PharmaceuticalsN/A3.253.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCBIOCrescent Biopharma75.19%CDXSCodexis78.54%DOMHDominari42.48%VNDAVanda Pharmaceuticals88.14%Insider OwnershipCompanyInsider OwnershipCBIOCrescent Biopharma4.00%CDXSCodexis2.10%DOMHDominari32.98%VNDAVanda Pharmaceuticals10.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCBIOCrescent Biopharma5019.55 million18.77 millionNo DataCDXSCodexis25082.85 million81.11 millionOptionableDOMHDominari414.64 million9.81 millionNot OptionableVNDAVanda Pharmaceuticals29059.09 million53.18 millionOptionableDOMH, VNDA, CBIO, and CDXS HeadlinesRecent News About These CompaniesVanda Pharmaceuticals (NASDAQ:VNDA) Posts Earnings Results, Misses Expectations By $0.12 EPSAugust 3, 2025 | marketbeat.comVanda Pharmaceuticals (NASDAQ:VNDA) Downgraded by Wall Street Zen to Strong SellAugust 3, 2025 | marketbeat.comVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Sees Large Increase in Short InterestAugust 3, 2025 | americanbankingnews.comShort Interest in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Increases By 2,603.2%August 2, 2025 | marketbeat.com190,536 Shares in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Acquired by Universal Beteiligungs und Servicegesellschaft mbHAugust 2, 2025 | marketbeat.comVanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q2 2025 Earnings Call TranscriptAugust 1, 2025 | msn.comVanda (VNDA) Q2 Revenue Rises 4%August 1, 2025 | fool.comVanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Reports Second Quarter 2025 Financial ResultsAugust 1, 2025 | finanznachrichten.deVanda Pharmaceuticals Inc. (VNDA) Q2 2025 Earnings Call TranscriptJuly 31, 2025 | seekingalpha.comVanda Pharmaceuticals (VNDA) Reports Q2 Loss, Misses Revenue EstimatesJuly 31, 2025 | zacks.comVanda Pharmaceuticals Q2 2025 Earnings: EPS Misses at -$0.46, Revenue Falls Short at $52.6 MillionJuly 31, 2025 | gurufocus.comVanda Pharmaceuticals misses top-line and bottom-line estimates; reaffirms FY25 outlookJuly 31, 2025 | seekingalpha.comVanda Pharmaceuticals Reports Second Quarter 2025 Financial ResultsJuly 31, 2025 | prnewswire.comGSA Capital Partners LLP Acquires 121,797 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)July 31, 2025 | marketbeat.comVanda Pharmaceuticals Q2 Earnings PreviewJuly 30, 2025 | msn.comMonaco Asset Management SAM Lowers Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)July 30, 2025 | marketbeat.comVanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025 | VNDA ...July 23, 2025 | gurufocus.comVanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025July 23, 2025 | prnewswire.comVanda Pharmaceuticals (VNDA) to Release Earnings on WednesdayJuly 23, 2025 | marketbeat.comVanda Pharmaceuticals (NASDAQ:VNDA) Stock Price Crosses Above 200 Day Moving Average - Here's What HappenedJuly 10, 2025 | marketbeat.comVNDA - Vanda Pharmaceuticals Inc Executives - MorningstarJuly 9, 2025 | morningstar.comMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDOMH, VNDA, CBIO, and CDXS Company DescriptionsCrescent Biopharma NASDAQ:CBIO$12.85 +1.85 (+16.82%) As of 08/8/2025 04:00 PM EasternCrescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.Codexis NASDAQ:CDXS$2.77 -0.01 (-0.36%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$2.76 0.00 (-0.18%) As of 08/8/2025 06:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.Dominari NASDAQ:DOMH$5.73 -0.01 (-0.17%) As of 08/8/2025 04:00 PM EasternDominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.Vanda Pharmaceuticals NASDAQ:VNDA$4.20 0.00 (0.00%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$4.28 +0.08 (+1.79%) As of 08/8/2025 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/04 - 08/08 Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact? Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
